An official American Thoracic Society statement: Diagnosis and management of beryllium sensitivity and chronic beryllium disease

American Journal of Respiratory and Critical Care Medicine

Volumn 190, Issue 10, 2014, Pages e34-e59

  Balmes, John R ^a   Abraham, Jerrold L ^a   Dweik, Raed A ^a   Fireman, Elizabeth ^a   Fontenot, Andrew P ^a   Maier, Lisa A ^a   Muller Quernheim, Joachim ^a   Ostiguy, Gaston ^a   Pepper, Lewis D ^a   Saltini, Cesare ^a   Schuler, Christine R ^a   Takaro, Tim K ^a   Wambach, Paul F ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

BERYLLIUM; HLA DPB1 ANTIGEN;

ARTICLE; AWARENESS; BERYLLIOSIS; BERYLLIUM SENSITIVITY; CHRONIC BERYLLIUM DISEASE; CLINICAL EVALUATION; CORTICOSTEROID THERAPY; DIAGNOSTIC PROCEDURE; DISEASE COURSE; EPIDEMIOLOGY; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GRANULOMATOSIS; HUMAN; IMMUNOPATHOGENESIS; INFLAMMATION; LUNG FUNCTION; LYMPHOCYTE PROLIFERATION TEST; MEDICAL SOCIETY; MEDLINE; OCCUPATIONAL DISEASE; OCCUPATIONAL EXPOSURE; OCCUPATIONAL HAZARD; PERIODIC MEDICAL EXAMINATION; PRIORITY JOURNAL; PROTECTIVE EQUIPMENT; WORKPLACE; CHRONIC DISEASE; HYPERSENSITIVITY; TOXICITY;

BERYLLIOSIS; BERYLLIUM; CHRONIC DISEASE; HUMANS; HYPERSENSITIVITY; OCCUPATIONAL EXPOSURE;

EID: 84925357989     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.201409-1722ST     Document Type: Article

References (158)

1. National Institute for Occupational Safety and Health. Preventing sensitization and disease from beryllium exposure. Cincinnati, OH: Department of Health and Human Services, CDC/NIOSH; 2011. DHHS publication (NIOSH) 2011-107.
2. Henneberger PK, Goe SK, Miller WE, Doney B, Groce DW. Industries in the United States with airborne beryllium exposure and estimates of the number of current workers potentially exposed. J Occup Environ Hyg 2004;1:648-659.
3. Tarlo SM, Rhee K, Powell E, Amer E, Newman L, Liss G, Jones N. Marked tachypnea in siblings with chronic beryllium disease due to copper-beryllium alloy. Chest 2001;119:647-650.
4. Lombardi G, Germain C, Uren J, Fiorillo MT, du Bois RM, Jones-Williams W, Saltini C, Sorrentino R, Lechler R. HLA-DP allele-specific T cell responses to beryllium account for DP-associated susceptibility to chronic beryllium disease. J Immunol 2001;166:3549-3555.
5. Marchand-Adam S, El Khatib A, Guillon F, Brauner MW, Lamberto C, Lepage V, Naccache JM, Valeyre D. Short- and long-term response to corticosteroid therapy in chronic beryllium disease. Eur Respir J 2008; 32:687-693.
6. Müller-Quernheim J, Gaede KI, Fireman E, Zissel G. Diagnoses of chronic beryllium disease within cohorts of sarcoidosis patients. Eur Respir J 2006;27:1190-1195.
7. Taiwo OA, Slade MD, Cantley LF, Fiellin MG, Wesdock JC, Bayer FJ, Cullen MR. Beryllium sensitization in aluminum smelter workers. J Occup Environ Med 2008;50:157-162.
8. Silva E, Bourin S, Sabounchi-Schütt F, Laurin Y, Barker E, Newman L, Eriksson H, Eklund A, Grunewald J. A quantitative proteomic analysis of soluble bronchoalveolar fluid proteins from patients with sarcoidosis and chronic beryllium disease. Sarcoidosis Vasc Diffuse Lung Dis 2007;24:24-32.
9. Fireman E, Kramer MR, Priel I, Lerman Y. Chronic beryllium disease among dental technicians in Israel. Sarcoidosis Vasc Diffuse Lung Dis 2006;23:215-221.
10. Nagaoka K, Yoshida T, Sakakibara H, Kurita H, Taniwaki H, Ono Y. Significant improvement from chronic beryllium disease following corticosteroid pulse therapy. Ind Health 2006;44: 296-301.
11. Weber H, Engelhardt WE. Anwendung bei der Untersuchungen von Stauben aus der Berylliumgewinnung. Zentralbl Gewerbehyg Unfallverhut 1933;10:41-47.
12. Zamakhovskaia EM, Martsinkovski BD, Syrochkovski EE. On the question of effect of beryllium fluoride on organism [in Russian]. Gig Tr I Tekh Besopasnost 1933;2:23.
13. Gelman I. Poisoning by vapors of beryllium oxyfluoride. J Ind Hyg Toxicol 1936;18:371-399.
14. VanORDSTRAND HS, Hughes R, DeNardi JM, Carmody MG. Beryllium poisoning. J Am Med Assoc 1945;129:1084-1090.
15. Hardy HL, Tabershaw IR. Delayed chemical pneumonitis occurring in workers exposed to beryllium compounds. J Ind Hyg Toxicol 1946; 28:197-211.
16. Eisenbud M, Wanta RC, Dustan C, Steadman LT, Harris WB, Wolf BS. Non-occupational berylliosis. J Ind Hyg Toxicol 1949;31:282-294.
17. Sterner JH, Eisenbud M. Epidemiology of beryllium intoxication. AMA Arch Ind Hyg Occup Med 1951;4:123-151.
18. Leiben J, Metzner F. Epidemiological findings associated with beryllium extraction. Am Ind Hyg Assoc J 1959;Dec:494-499.
19. Hardy HL, Rabe EW, Lorch S. United States, Beryllium Case Registry (1952-1966). Review of its methods and utility. J Occup Med 1967;9: 271-276.
20. Eisenbud M, Lisson J. Epidemiological aspects of beryllium-induced nonmalignant lung disease: a 30-year update. J Occup Med 1983; 25:196-202.
21. Eisenbud M. Origins of the standards for control of beryllium disease (1947-1949). Environ Res 1982;27:79-88.
22. Occupational Safety and Health Administration. Occupational exposure to beryllium, 29 C.F.R. Part 1910. 1975.
23. Centers for Disease Control (CDC). Beryllium disease among workers in a spacecraft-manufacturing plant - California. MMWR Morb Mortal Wkly Rep 1983;32:419-420, 425.
24. Cullen MR, Kominsky JR, Rossman MD, Cherniack MG, Rankin JA, Balmes JR, Kern JA, Daniele RP, Palmer L, Naegel GP, et al. Chronic beryllium disease in a precious metal refinery. Clinical epidemiologic and immunologic evidence for continuing risk from exposure to low level beryllium fume. Am Rev Respir Dis 1987;135:201-208.
25. National Institute for Occupational Safety and Health. NIOSH pocket guide to chemical hazards. Washington, D.C.: US Government Printing Office. DHHS (NIOSH) Publication No. 2005-149. 2005 [accessed 2009 August 11]. Available from: http://www.cdc.gov/niosh/npg/npgd0054.html
26. Chronic Beryllium Disease Prevention Program. Final Rule. Code of Federal Regulations, Title 10, Part 850. [accessed 2014 Oct 28]. Available from: http://www.gpo.gov/fdsys/pkg/FR-1999-12-08/pdf/99-31181.pdf
27. American Conference of Governmental Industrial Hygienists. 2009 TLVs and BEIs. Cincinnati, OH: American Conference of Governmental Industrial Hygienists; 2009.
28. Rossman MD, Kern JA, Elias JA, Cullen MR, Epstein PE, Preuss OP, Markham TN, Daniele RP. Proliferative response of bronchoalveolar lymphocytes to beryllium: a test for chronic beryllium disease. Ann Intern Med 1988;108:687-693.
29. Kreiss K, Newman LS, Mroz MM, Campbell PA. Screening blood test identifies subclinical beryllium disease. J Occup Med 1989;31: 603-608.
30. Mroz MM, Kreiss K, Lezotte DC, Campbell PA, Newman LS. Reexamination of the blood lymphocyte transformation test in the diagnosis of chronic beryllium disease. J Allergy Clin Immunol 1991; 88:54-60.
31. Kreiss K, Mroz MM, Zhen B, Martyny JW, Newman LS. Epidemiology of beryllium sensitization and disease in nuclear workers. Am Rev Respir Dis 1993;148:985-991.
32. Kreiss K, Mroz MM, Newman LS, Martyny J, Zhen B. Machining risk of beryllium disease and sensitization with median exposures below 2 micrograms/m3. Am J Ind Med 1996;30:16-25.
33. Kreiss K, Mroz MM, Zhen B, Wiedemann H, Barna B. Risks of beryllium disease related to work processes at a metal, alloy, and oxide production plant. Occup Environ Med 1997;54:605-612.
34. Henneberger PK, Cumro D, Deubner DD, Kent MS, McCawley M, Kreiss K. Beryllium sensitization and disease among long-term and short-term workers in a beryllium ceramics plant. Int Arch Occup Environ Health 2001;74:167-176.
35. Deubner D, Kelsh M, Shum M, Maier L, Kent M, Lau E. Beryllium sensitization, chronic beryllium disease, and exposures at a beryllium mining and extraction facility. Appl Occup Environ Hyg 2001;16: 579-592.
36. Sackett HM, Maier LA, Silveira LJ, Mroz MM, Ogden LG, Murphy JR, Newman LS. Beryllium medical surveillance at a former nuclear weapons facility during cleanup operations. J Occup Environ Med 2004;46:953-961.
37. Schuler CR, Kent MS, Deubner DC, Berakis MT, McCawley M, Henneberger PK, Rossman MD, Kreiss K. Process-related risk of beryllium sensitization and disease in a copper-beryllium alloy facility. Am J Ind Med 2005;47:195-205.
38. Stanton ML, Henneberger PK, Kent MS, Deubner DC, Kreiss K, Schuler CR. Sensitization and chronic beryllium disease among workers in copper-beryllium distribution centers. J Occup Environ Med 2006; 48:204-211.
39. Kreiss K, Wasserman S, Mroz MM, Newman LS. Beryllium disease screening in the ceramics industry. Blood lymphocyte test performance and exposure-disease relations. J Occup Med 1993;35: 267-274.
40. Welch L, Ringen K, Bingham E, Dement J, Takaro T, McGowan W, Chen A, Quinn P. Screening for beryllium disease among construction trade workers at Department of Energy nuclear sites. Am J Ind Med 2004;46:207-218.
41. Rosenman K, Hertzberg V, Rice C, Reilly MJ, Aronchick J, Parker JE, Regovich J, Rossman M. Chronic beryllium disease and sensitization at a beryllium processing facility. Environ Health Perspect 2005; 113:1366-1372. [Published erratum appears in Environ Health Perspect 114:A214.]
42. Rodrigues EG, McClean MD, Weinberg J, Pepper LD. Beryllium sensitization and lung function among former workers at the Nevada Test Site. Am J Ind Med 2008;51:512-523.
43. Mikulski MA, Sanderson WT, Leonard SA, Lourens S, Field RW, Sprince NL, Fuortes LJ. Prevalence of beryllium sensitization among Department of Defense conventional munitions workers at low risk for exposure. J Occup Environ Med 2011;53:258-265.
44. Stange AW, Furman FJ, Hilmas DE. Rocky Flats beryllium health surveillance. Environ Health Perspect 1996;104:981-986.
45. Stange AW, Hilmas DE, Furman FJ, Gatliffe TR. Beryllium sensitization and chronic beryllium disease at a former nuclear weapons facility. Appl Occup Environ Hyg 2001;16:405-417.
46. Newman LS, Mroz MM, Maier LA, Daniloff EM, Balkissoon R. Efficacy of serial medical surveillance for chronic beryllium disease in a beryllium machining plant. J Occup Environ Med 2001;43: 231-237.
47. Schuler CR, Kitt MM, Henneberger PK, Deubner DC, Kreiss K. Cumulative sensitization and disease in a beryllium oxide ceramics worker cohort. J Occup Environ Med 2008;50:1343-1350.
48. Cummings KJ, Deubner DC, Day GA, Henneberger PK, Kitt MM, Kent MS, Kreiss K, Schuler CR. Enhanced preventive programme at a beryllium oxide ceramics facility reduces beryllium sensitisation among new workers. Occup Environ Med 2007;64:134-140.
49. Thomas CA, Bailey RL, Kent MS, Deubner DC, Kreiss K, Schuler CR. Efficacy of a program to prevent beryllium sensitization among new employees at a copper-beryllium alloy processing facility. Public Health Rep 2009;124:112-124.
50. Bailey RL, Thomas CA, Deubner DC, Kent MS, Kreiss K, Schuler CR. Evaluation of a preventive program to reduce sensitization at a beryllium metal, oxide, and alloy production plant. J Occup Environ Med 2010;52:505-512.
51. Kreiss K, Day GA, Schuler CR. Beryllium: a modern industrial hazard. Annu Rev Public Health 2007;28:259-277.
52. Newman LS, Mroz MM, Balkissoon R, Maier LA. Beryllium sensitization progresses to chronic beryllium disease: a longitudinal study of disease risk. Am J Respir Crit Care Med 2005;171:54-60.
53. Seidler A, Euler U, Müller-Quernheim J, Gaede KI, Latza U, Groneberg D, Letzel S. Systematic review: Progression of beryllium sensitization to chronic beryllium disease. Occup Med (Lond) 2012;62:506-513.
54. Harber P, Bansal S, Balmes J. Progression from beryllium exposure to chronic beryllium disease: an analytic model. Environ Health Perspect 2009;117:970-974.
55. Schuler CR, Virji MA, Deubner DC, Stanton ML, Stefaniak AB, Day GA, Park JY, Kent MS, Sparks R, Kreiss K. Sensitization and chronic beryllium disease at a primary manufacturing facility, part 3: exposure-response among short-term workers. Scand J Work Environ Health 2012;38:270-281.
56. Kelleher PC, Martyny JW, Mroz MM, Maier LA, Ruttenber AJ, Young DA, Newman LS. Beryllium particulate exposure and disease relations in a beryllium machining plant. J Occup Environ Med 2001; 43:238-249.
57. Arjomandi M, Seward J, Gotway MB, Nishimura S, Fulton GP, Thundiyil J, King TE Jr, Harber P, Balmes JR. Low prevalence of chronic beryllium disease among workers at a nuclear weapons research and development facility. J Occup Environ Med 2010;52:647-652.
58. Mikulski MA, Leonard SA, Sanderson WT, Hartley PG, Sprince NL, Fuortes LJ. Risk of beryllium sensitization in a low-exposed former nuclear weapons cohort from the Cold War era. Am J Ind Med 2011; 54:194-204.
59. Maier LA, Martyny JW, Liang J, Rossman MD. Recent chronic beryllium disease in residents surrounding a beryllium facility. Am J Respir Crit Care Med 2008;177:1012-1017.
60. Redlich CA, Welch LS. Chronic beryllium disease: risk from low-level exposure. Am J Respir Crit Care Med 2008;177:936-937.
61. Tinkle SS, Antonini JM, Rich BA, Roberts JR, Salmen R, DePree K, Adkins EJ. Skin as a route of exposure and sensitization in chronic beryllium disease. Environ Health Perspect 2003;111:1202-1208.
62. Stefaniak AB, Hoover MD, Day GA, Dickerson RM, Peterson EJ, Kent MS, Schuler CR, Breysse PN, Scripsick RC. Characterization of physicochemical properties of beryllium aerosols associated with prevalence of chronic beryllium disease. J Environ Monit 2004;6: 523-532.
63. Stefaniak AB, Hoover MD, Dickerson RM, Peterson EJ, Day GA, Breysse PN, Kent MS, Scripsick RC. Surface area of respirable beryllium metal, oxide, and copper alloy aerosols and implications for assessment of exposure risk of chronic beryllium disease. AIHA J (Fairfax, Va) 2003;64:297-305.
64. Cummings KJ, Stefaniak AB, Virji MA, Kreiss K. A reconsideration of acute Beryllium disease. Environ Health Perspect 2009;117:1250-1256.
65. Deubner DC, Sabey P, Huang W, Fernandez D, Rudd A, Johnson WP, Storrs J, Larson R. Solubility and chemistry of materials encountered by beryllium mine and ore extraction workers: relation to risk. J Occup Environ Med 2011;53:1187-1193.
66. Martyny JW, Hoover MD, Mroz MM, Ellis K, Maier LA, Sheff KL, Newman LS. Aerosols generated during beryllium machining. J Occup Environ Med 2000;42:8-18.
67. Stefaniak AB, Day GA, Hoover MD, Breysse PN, Scripsick RC. Differences in dissolution behavior in a phagolysosomal simulant fluid for single-constituent and multi-constituent materials associated with beryllium sensitization and chronic beryllium disease. Toxicol In Vitro 2006;20:82-95.
68. Stefaniak AB, Virji MA, Day GA. Release of beryllium into artificial airway epithelial lining fluid. Arch Environ Occup Health 2012;67:219-228.
69. Finch GL, Mewhinney JA, Hoover MD, Eidson AF, Haley PJ, Bice DE. Clearance, translocation, and excretion of beryllium following acute inhalation of beryllium oxide by beagle dogs. Fundam Appl Toxicol 1990;15:231-241.
70. Finch GL, Mewhinney JA, Eidson AF, Hoover MD, Rothenberg SJ. In vitro dissolution characteristics of beryllium oxide and beryllium metal aerosols. J Aerosol Sci 1988;19:333-342.
71. Eidson AF, Taya A, Finch GL, Hoover MD, Cook C. Dosimetry of beryllium in cultured canine pulmonary alveolar macrophages. J Toxicol Environ Health 1991;34:433-448.
72. Day GA, Hoover MD, Stefaniak AB, Dickerson RM, Peterson EJ, Esmen NA, Scripsick RC. Bioavailability of beryllium oxide particles: an in vitro study in the murine J774A.1 macrophage cell line model. Exp Lung Res 2005;31:341-360.
73. Virji MA, Stefaniak AB, Day GA, Stanton ML, Kent MS, Kreiss K, Schuler CR. Characteristics of beryllium exposure to small particles at a beryllium production facility. Ann Occup Hyg 2011;55:70-85.
74. Richeldi L, Kreiss K, Mroz MM, Zhen B, Tartoni P, Saltini C. Interaction of genetic and exposure factors in the prevalence of berylliosis. Am J Ind Med 1997;32:337-340.
75. Saltini C, Kirby M, Trapnell BC, Tamura N, Crystal RG. Biased accumulation of T lymphocytes with "memory"-type CD45 leukocyte common antigen gene expression on the epithelial surface of the human lung. J Exp Med 1990;171:1123-1140.
76. Saltini C, Winestock K, Kirby M, Pinkston P, Crystal RG. Maintenance of alveolitis in patients with chronic beryllium disease by beryllium-specific helper T cells. N Engl J Med 1989;320:1103-1109.
77. +) T cells in patients with chronic beryllium disease. J Clin Invest 2002;110:1473-1482.
78. Fontenot AP, Kotzin BL, Comment CE, Newman LS. Expansions of T-cell subsets expressing particular T-cell receptor variable regions in chronic beryllium disease. Am J Respir Cell Mol Biol 1998;18:581-589.
79. Richeldi L, Sorrentino R, Saltini C. HLA-DPB1 glutamate 69: a genetic marker of beryllium disease. Science 1993;262:242-244.
80. Snyder JA, Demchuk E, McCanlies EC, Schuler CR, Kreiss K, Andrew ME, Frye BL, Ensey JS, Stanton ML, Weston A. Impact of negatively charged patches on the surface of MHC class II antigen-presenting proteins on risk of chronic beryllium disease. J R Soc Interface 2008;5:749-758.
81. Maier LA, McGrath DS, Sato H, Lympany P, Welsh K, Du Bois R, Silveira L, Fontenot AP, Sawyer RT, Wilcox E, et al. Influence of MHC class II in susceptibility to beryllium sensitization and chronic beryllium disease. J Immunol 2003;171:6910-6918.
82. McCanlies EC, Ensey JS, Schuler CR, Kreiss K, Weston A. The association between HLA-DPB1Glu69 and chronic beryllium disease and beryllium sensitization. Am J Ind Med 2004;46:95-103.
83. Rossman MD, Stubbs J, Lee CW, Argyris E, Magira E, Monos D. Human leukocyte antigen Class II amino acid epitopes: susceptibility and progression markers for beryllium hypersensitivity. Am J Respir Crit Care Med 2002;165:788-794.
84. Saltini C, Richeldi L, Losi M, Amicosante M, Voorter C, van den Berg-Loonen E, Dweik RA, Wiedemann HP, Deubner DC, Tinelli C. Major histocompatibility locus genetic markers of beryllium sensitization and disease. Eur Respir J 2001;18:677-684.
85. Wang Z, Farris GM, Newman LS, Shou Y, Maier LA, Smith HN, Marrone BL. Beryllium sensitivity is linked to HLA-DP genotype. Toxicology 2001;165:27-38.
86. Wang Z, White PS, Petrovic M, Tatum OL, Newman LS, Maier LA, Marrone BL. Differential susceptibilities to chronic beryllium disease contributed by different Glu69 HLA-DPB1 and -DPA1 alleles. J Immunol 1999;163:1647-1653.
87. Weston A, Snyder J, McCanlies EC, Schuler CR, Andrew ME, Kreiss K, Demchuk E. Immunogenetic factors in beryllium sensitization and chronic beryllium disease. Mutat Res 2005;592:68-78.
88. Amicosante M, Berretta F, Rossman M, Butler RH, Rogliani P, van den Berg-Loonen E, Saltini C. Identification of HLA-DRPhebeta47 as the susceptibility marker of hypersensitivity to beryllium in individuals lacking the berylliosis-associated supratypic marker HLA-DPGlubeta69. Respir Res 2005;6:94.
89. Van Dyke MV, Martyny JW, Mroz MM, Silveira LJ, Strand M, Cragle DL, Tankersley WG, Wells SM, Newman LS, Maier LA. Exposure and genetics increase risk of beryllium sensitisation and chronic beryllium disease in the nuclear weapons industry. Occup Environ Med 2011; 68:842-848.
90. Van Dyke MV, Martyny JW, Mroz MM, Silveira LJ, Strand M, Fingerlin TE, Sato H, Newman LS, Maier LA. Risk of chronic beryllium disease by HLA-DPB1 E69 genotype and beryllium exposure in nuclear workers. Am J Respir Crit Care Med 2011;183:1680-1688.
91. Fontenot AP, Falta MT, Freed BM, Newman LS, Kotzin BL. Identification of pathogenic T cells in patients with beryllium-induced lung disease. J Immunol 1999;163:1019-1026.
92. + T cells underlies disease-susceptibility HLA-DP alleles in chronic beryllium disease. Proc Natl Acad Sci USA 2000;97:12717-12722.
93. Fontenot AP, Newman LS, Kotzin BL. Chronic beryllium disease: T cell recognition of a metal presented by HLA-DP. Clin Immunol 2001; 100:4-14.
94. Fontenot AP, Kotzin BL. Chronic beryllium disease: immune-mediated destruction with implications for organ-specific autoimmunity. Tissue Antigens 2003;62:449-458.
95. Tinkle SS, Kittle LA, Schumacher BA, Newman LS. Beryllium induces IL-2 and IFN-g in berylliosis. J Immunol 1997;158:518-526.
96. + T cells is dependent on a single amino acid residue of the MHC class II β-chain. J Immunol 2005;175:7029-7037.
97. Freiman DG, Hardy HL. Beryllium disease. The relation of pulmonary pathology to clinical course and prognosis based on a study of 130 cases from the U.S. beryllium case registry. Hum Pathol 1970;1: 25-44.
98. Dutra FR. Experimental beryllium granulomas of the skin. AMA Arch Ind Hyg Occup Med 1951;3:81-89.
99. Dutra FR. The pneumonitis and granulomatosis peculiar to beryllium workers. Am J Pathol 1948;24:1137-1165.
100. Williams WJ. United Kingdom Beryllium Registry: mortality and autopsy study. Environ Health Perspect 1996;104:949-951.
101. Verma DK, Ritchie AC, Shaw ML. Measurement of beryllium in lung tissue of a chronic beryllium disease case and cases with sarcoidosis. Occup Med (Lond) 2003;53:223-227.
102. Sawyer RT, Abraham JL, Daniloff E, Newman LS. Secondary ion mass spectroscopy demonstrates retention of beryllium in chronic beryllium disease granulomas. J Occup Environ Med 2005;47: 1218-1226.
103. Butnor KJ, Sporn TA, Ingram P, Gunasegaram S, Pinto JF, Roggli VL. Beryllium detection in human lung tissue using electron probe X-ray microanalysis. Mod Pathol 2003;16:1171-1177.
104. Williams WR, Williams WJ. Development of beryllium lymphocyte transformation tests in chronic beryllium disease. Int Arch Allergy Appl Immunol 1982;67:175-180.
105. Williams WJ, Williams WR. Value of beryllium lymphocyte transformation tests in chronic beryllium disease and in potentially exposed workers. Thorax 1983;38:41-44.
106. Barna BP, Culver DA, Yen-Lieberman B, Dweik RA, Thomassen MJ. Clinical application of beryllium lymphocyte proliferation testing. Clin Diagn Lab Immunol 2003;10:990-994.
107. Stange AW, Furman FJ, Hilmas DE. The beryllium lymphocyte proliferation test: relevant issues in beryllium health surveillance. Am J Ind Med 2004;46:453-462.
108. Newman LS. Significance of the blood beryllium lymphocyte proliferation test. Environ Health Perspect 1996;104:953-956.
109. Deubner DC, Goodman M, Iannuzzi J. Variability, predictive value, and uses of the beryllium blood lymphocyte proliferation test (BLPT): preliminary analysis of the ongoing workforce survey. Appl Occup Environ Hyg 2001;16:521-526.
110. U.S. Department of Energy. Beryllium lymphocyte proliferation testing. Washington, DC: US Government Printing Office; 2001.
111. Middleton DC, Lewin MD, Kowalski PJ, Cox SS, Kleinbaum D. The BeLPT: algorithms and implications. Am J Ind Med 2006;49:36-44.
112. Middleton DC, Fink J, Kowalski PJ, Lewin MD, Sinks T. Optimizing BeLPT criteria for beryllium sensitization. Am J Ind Med 2008;51:166-172.
113. Stokes RF, Rossman MD. Blood cell proliferation response to beryllium: analysis by receiver-operating characteristics. J Occup Med 1991;33:23-28.
114. Yoshida T, Shima S, Nagaoka K, Taniwaki H, Wada A, Kurita H, Morita K. A study on the beryllium lymphocyte transformation test and the beryllium levels in working environment. Ind Health 1997;35:374-379.
115. Donovan EP, Kolanz ME, Galbraith DA, Chapman PS, Paustenbach DJ. Performance of the beryllium blood lymphocyte proliferation test based on a long-term occupational surveillance program. Int Arch Occup Environ Health 2007;81:165-178.
116. Curtis GH. Cutaneous hypersensitivity due to beryllium; a study of thirteen cases. AMA Arch Derm Syphilol 1951;64:470-482.
117. Rossman MD. Chronic beryllium disease: diagnosis and management. Environ Health Perspect 1996;104:945-947.
118. National Research Council. Managing health effects of beryllium. Washington, DC: The National Academies Press; 2008.
119. Middleton DC, Mayer AS, Lewin MD, Mroz MM, Maier LA. Interpreting borderline BeLPT results. Am J Ind Med 2011;54:205-209.
120. Newman LS, Kreiss K, King TE Jr, Seay S, Campbell PA. Pathologic and immunologic alterations in early stages of beryllium disease. Re-examination of disease definition and natural history. Am Rev Respir Dis 1989;139:1479-1486.
121. U.S. Department of Labor. Office of Workers' Compensation Programs. Chronic beryllium disease and beryllium sensitivity under the Energy Employees Occupational Illness Compensation Program Act [accessed 2014 Oct 29]. Available from: http://www.dol.gov/owcp/energy/regs/compliance/brochure/Beryllium-Brochure.pdf
122. Maier LA. Beryllium health effects in the era of the beryllium lymphocyte proliferation test. Appl Occup Environ Hyg 2001;16:514-520.
123. Stoeckle JD, Hardy HL, Weber AL. Chronic beryllium disease. Longterm follow-up of sixty cases and selective review of the literature. Am J Med 1969;46:545-561.
124. Hall TC, Wood CH, Stoeckle JD, Tepper LB. Case data from the beryllium registry. AMA Arch Ind Health 1959;19:100-103.
125. Sprince NL, Kazemi H, Hardy HL. Current (1975) problem of differentiating between beryllium disease and sarcoidosis. Ann N Y Acad Sci 1976;278:654-664.
126. Kriebel D, Brain JD, Sprince NL, Kazemi H. The pulmonary toxicity of beryllium. Am Rev Respir Dis 1988;137:464-473.
127. Berlin JM, Taylor JS, Sigel JE, Bergfeld WF, Dweik RA. Beryllium dermatitis. J Am Acad Dermatol 2003;49:939-941.
128. Kanarek DJ, Wainer RA, Chamberlin RI, Weber AL, Kazemi H. Respiratory illness in a population exposed to beryllium. Am Rev Respir Dis 1973;108:1295-1302.
129. Aronchick JM, Rossman MD, Miller WT. Chronic beryllium disease: diagnosis, radiographic findings, and correlation with pulmonary function tests. Radiology 1987;163:677-682.
130. Pappas GP, Newman LS. Early pulmonary physiologic abnormalities in beryllium disease. Am Rev Respir Dis 1993;148:661-666.
131. Newman LS, Buschman DL, Newell JD Jr, Lynch DA. Beryllium disease: assessment with CT. Radiology 1994;190:835-840.
132. Harris KM, McConnochie K, Adams H. The computed tomographic appearances in chronic berylliosis. Clin Radiol 1993;47:26-31.
133. Iles PB. Multiple bronchial stenoses: treatment by mechanical dilatation. Thorax 1981;36:784-786.
134. Gevenois PA, Vande Weyer R, De Vuyst P. Beryllium disease: assessment with CT. Radiology 1994;193:283-284.
135. Daniloff EM, Lynch DA, Bartelson BB, Newell JD Jr, Bernstein SM, Newman LS. Observer variation and relationship of computed tomography to severity of beryllium disease. Am J Respir Crit Care Med 1997;155:2047-2056.
136. Fireman E, Haimsky E, Noiderfer M, Priel I, Lerman Y. Misdiagnosis of sarcoidosis in patients with chronic beryllium disease. Sarcoidosis Vasc Diffuse Lung Dis 2003;20:144-148.
137. Newman LS, Kreiss K. Nonoccupational beryllium disease masquerading as sarcoidosis: identification by blood lymphocyte proliferative response to beryllium. Am Rev Respir Dis 1992;145: 1212-1214.
138. Hunninghake GW, Costabel U, Ando M, Baughman R, Cordier JF, DuBois R, Eklund A, Kitaichi M, Lunch J, Rizzato G, et al. Statement on sarcoidosis. Joint Statement of the American Thoracic Society (ATS), the European Respiratory Society (ERS) and the World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG) adopted by the ATS Board of Directors and by the ERS Executive Committee, February 1999. Am J Respir Crit Care Med 1999;160:736-755.
139. Maier LA. Is smoking beneficial for granulomatous lung diseases?Am J Respir Crit Care Med 2004;169:893-895.
140. Tinkle SS, Newman LS. Beryllium-stimulated release of tumor necrosis factor-alpha, interleukin-6, and their soluble receptors in chronic beryllium disease. Am J Respir Crit Care Med 1997;156: 1884-1891.
141. Newman LS, Bobka C, Schumacher B, Daniloff E, Zhen B, Mroz MM, King TE Jr. Compartmentalized immune response reflects clinical severity of beryllium disease. Am J Respir Crit Care Med 1994;150: 135-142.
142. Wang ML, Avashia BH, Petsonk EL. Interpreting periodic lung function tests in individuals: the relationship between 1- to 5-year and long-term FEV1 changes. Chest 2006;130:493-499.
143. Mroz MM, Maier LA, Strand M, Silviera L, Newman LS. Beryllium lymphocyte proliferation test surveillance identifies clinically significant beryllium disease. Am J Ind Med 2009;52:762-773.
144. Duggal M, Deubner DC, Curtis AM, Cullen MR. Long-term follow-up of beryllium sensitized workers from a single employer. BMC Public Health 2010;10:5.
145. Handa T, Nagai S, Kitaichi M, Chin K, Ito Y, Oga T, Takahashi K, Watanabe K, Mishima M, Izumi T. Long-term complications and prognosis of chronic beryllium disease. Sarcoidosis Vasc Diffuse Lung Dis 2009;26:24-31.
146. Sood A, Beckett WS, Cullen MR. Variable response to long-term corticosteroid therapy in chronic beryllium disease. Chest 2004; 126:2000-2007.
147. Sood A. Current treatment of chronic beryllium disease. J Occup Environ Hyg 2009;6:762-765.
148. Denardi JM. Long-term experience with beryllium disease. AMA Arch Ind Health 1959;19:110-116.
149. Seeler AO. Treatment of chronic beryllium poisoning. AMA Arch Ind Health 1959;19:164-168.
150. Deubner D, Kent M. Keeping beryllium workers safe: an enhanced preventive model. J Occup Environ Hyg 2007;4:D23-D30.
151. US Department of Energy. Office of Health, Safety and Security. Chronic Beryllium Disease Prevention Program [accessed 2014 Oct 29]. Available from: http://energy.gov/ehss/chronic-beryllium-disease-prevention-program-10-cfr-850
152. Borak J, Woolf SH, Fields CA. Use of beryllium lymphocyte proliferation testing for screening of asymptomatic individuals: an evidence-based assessment. J Occup Environ Med 2006;48:937-947.
153. McCaig K. Estimation of industries and occupations with potential exposure to beryllium in British Columbia. School of Occupational and Environmental Hygiene, University of British Columbia; April 2006.
154. Kolanz ME, Madl AK, Kelsh MA, Kent MS, Kalmes RM, Paustenbach DJ. A comparison and critique of historical and current exposure assessment methods for beryllium: implications for evaluating risk of chronic beryllium disease. Appl Occup Environ Hyg 2001;16: 593-614.
155. Madl AK, Unice K, Brown JL, Kolanz ME, Kent MS. Exposure-response analysis for beryllium sensitization and chronic beryllium disease among workers in a beryllium metal machining plant. J Occup Environ Hyg 2007;4:448-466.
156. National Institute for Occupational Safety and Health. NIOSH alert: preventing sensitization and disease from beryllium exposure [accessed 2014 Oct 29]. Available from: http://www.cdc.gov/niosh/ docs/2011-107/pdfs/2011-107.pdf
157. US Census Bureau. 1987 SIC and 2002 NAICS Correspondence Tables Web site. 2003 Apr 29 [accessed 2010 Jun 28]. Available from: http://www.census.gov/eos/www/naics/
158. Willis HH, Florig HK. Potential exposures and risks from beryllium-containing products. Risk Anal 2002;22:1019-1033.